Merck projects 5%-7% revenue increase in 2024, despite Keytruda patent expiration in 2028.
Merck has achieved a 72% return over the past five years, largely driven by its Keytruda immunotherapy, which generated $26.3 billion in sales last year. However, Keytruda's patent will expire by 2028, raising investor concerns. Merck projects a 5% to 7% revenue increase in 2024, with an earnings-per-share target of $7.94 to $8.04. While the company is diversifying its portfolio, the challenge remains to find growth post-Keytruda.
September 14, 2024
3 Articles